Key result
High potency and depot neuroleptics linked to more frequent, dose-independent neuroleptic malignant syndrome.
Key points are not available for this paper at this time.
Design
Review
Monitor closely for neuroleptic malignant syndrome in the first 9 days after high-potency or depot antipsychotics; leaves open dose-independent mechanisms for prospective study.
The neuroleptic malignant syndrome (NMS) involves fever, extrapyramidal rigidity, and disturbances of autonomic function and consciousness. It occurs more often with high potency and depot forms, frequently 3 to 9 days after initiation and sometimes years later, and is not related to dose or previou
No takes yet. Share an insight, caveat, or question.
Chester Pearlman (1992) studied this question. High potency and depot neuroleptics are more frequently associated with neuroleptic malignant syndrome, which typically occurs 3 to 9 days after initiation and is not related to dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: